Amgen Future Growth

Future criteria checks 2/6

Amgen is forecast to grow earnings and revenue by 8.9% and 4.4% per annum respectively. EPS is expected to grow by 10.4% per annum. Return on equity is forecast to be 379.7% in 3 years.

Key information

8.9%

Earnings growth rate

10.4%

EPS growth rate

Biotechs earnings growth	21.3%
Revenue growth rate	4.4%
Future return on equity	379.7%
Analyst coverage	Good
Last updated	22 Apr 2024

Recent future growth updates

Recent updates

Amgen: Weight Loss Drug Candidate Debate A Red Herring - Buying The Dip Advisable

Feb 08

Amgen: Accelerating The Business And Dividend Growth

Jan 29

Is Amgen Inc. (NASDAQ:AMGN) Trading At A 44% Discount?

Jan 29

Up 40%, 3%-Yielding Amgen Is Still One Of My Favorite Healthcare Stocks

Jan 22

Is Amgen (NASDAQ:AMGN) A Risky Investment?

Dec 28

Here's Why Amgen (NASDAQ:AMGN) Has Caught The Eye Of Investors

Dec 13

Are Investors Undervaluing Amgen Inc. (NASDAQ:AMGN) By 46%?

Oct 23

Is Amgen (NASDAQ:AMGN) Using Too Much Debt?

Sep 22

Do Amgen's (NASDAQ:AMGN) Earnings Warrant Your Attention?

Sep 04

Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.13

Aug 05

Amgen Inc. (NASDAQ:AMGN) Shares Could Be 45% Below Their Intrinsic Value Estimate

May 30

Amgen (NASDAQ:AMGN) Is Paying Out A Larger Dividend Than Last Year

May 09

These 4 Measures Indicate That Amgen (NASDAQ:AMGN) Is Using Debt Reasonably Well

Apr 29

Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.13

Apr 05

Amgen Inc. (NASDAQ:AMGN) Shares Could Be 37% Below Their Intrinsic Value Estimate

Feb 27

Earnings and Revenue Growth Forecasts

NasdaqGS:AMGN - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	35,084	8,119	12,600	13,055	20
12/31/2025	34,144	7,560	12,277	12,588	27
12/31/2024	32,951	6,121	14,115	13,362	28
12/31/2023	28,190	6,717	7,359	8,471	N/A
9/30/2023	26,833	7,566	9,379	10,582	N/A
6/30/2023	26,582	7,979	9,685	10,800	N/A
3/31/2023	26,190	7,917	7,531	8,621	N/A
12/31/2022	26,323	6,552	8,785	9,721	N/A
9/30/2022	26,330	6,835	8,997	9,880	N/A
6/30/2022	26,384	6,576	8,355	9,320	N/A
3/31/2022	26,316	5,723	8,417	9,321	N/A
12/31/2021	25,979	5,893	8,381	9,261	N/A
9/30/2021	25,767	5,609	7,840	8,606	N/A
6/30/2021	25,484	5,746	8,897	9,556	N/A
3/31/2021	25,164	7,085	9,835	10,467	N/A
12/31/2020	25,424	7,264	9,889	10,497	N/A
9/30/2020	24,987	7,352	10,235	10,858	N/A
6/30/2020	24,301	7,299	10,209	10,867	N/A
3/31/2020	23,966	7,675	8,795	9,439	N/A
12/31/2019	23,362	7,842	8,532	9,150	N/A
9/30/2019	23,395	8,067	9,175	9,830	N/A
6/30/2019	23,562	7,958	9,070	9,726	N/A
3/31/2019	23,750	8,075	9,715	10,414	N/A
12/31/2018	23,747	8,394	10,558	11,296	N/A
9/30/2018	23,319	2,202	10,448	11,114	N/A
6/30/2018	23,188	2,364	10,642	11,295	N/A
3/31/2018	22,939	2,219	10,868	11,519	N/A
12/31/2017	22,849	1,979	10,513	11,177	N/A
9/30/2017	23,012	8,178	N/A	11,265	N/A
6/30/2017	23,050	8,174	N/A	10,473	N/A
3/31/2017	22,928	7,893	N/A	10,824	N/A
12/31/2016	22,991	7,722	N/A	10,354	N/A
9/30/2016	22,562	7,587	N/A	9,327	N/A
6/30/2016	22,474	7,433	N/A	9,557	N/A
3/31/2016	22,156	7,216	N/A	10,164	N/A
12/31/2015	21,662	6,939	N/A	9,731	N/A
9/30/2015	21,457	6,433	N/A	10,103	N/A
6/30/2015	20,765	5,814	N/A	9,952	N/A
3/31/2015	20,575	5,708	N/A	8,895	N/A
12/31/2014	20,063	5,158	N/A	8,952	N/A
9/30/2014	19,743	4,885	N/A	7,945	N/A
6/30/2014	19,460	5,009	N/A	7,011	N/A
3/31/2014	18,959	4,720	N/A	6,384	N/A
12/31/2013	18,676	5,081	N/A	6,291	N/A
9/30/2013	17,980	4,848	N/A	5,268	N/A
6/30/2013	17,551	4,587	N/A	5,184	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AMGN's forecast earnings growth (8.9% per year) is above the savings rate (2.3%).

Earnings vs Market: AMGN's earnings (8.9% per year) are forecast to grow slower than the US market (14.7% per year).

High Growth Earnings: AMGN's earnings are forecast to grow, but not significantly.

Revenue vs Market: AMGN's revenue (4.4% per year) is forecast to grow slower than the US market (8.1% per year).

High Growth Revenue: AMGN's revenue (4.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: AMGN's Return on Equity is forecast to be very high in 3 years time (379.7%).

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Amgen Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 20%

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Inc. Provides Earnings Guidance for the Full Year 2023

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2023

Consensus EPS estimates fall by 12%

Recent updates

Amgen Inc., Annual General Meeting, May 31, 2024

Amgen: The Giant With An Impressive Pipeline

Is Amgen (NASDAQ:AMGN) Using Too Much Debt?

Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock

Amgen Will Benefit From Increased Medical Spending

Dividend of US$2.25 announced

Amgen Presents New Research on Otezla (Apremilast) at AAD 2024

Amgen Announces 2024 Second Quarter Dividend, Payable on June 7,2024

Amgen: A Good Dividend Growth Stock For The Watch List

Amgen's (NASDAQ:AMGN) Shareholders May Want To Dig Deeper Than Statutory Profit

Pinning Down Amgen Inc.'s (NASDAQ:AMGN) P/E Is Difficult Right Now

Consensus EPS estimates fall by 20%

Amgen: Weight Loss Drug Candidate Debate A Red Herring - Buying The Dip Advisable

New minor risk - Earnings quality

Upcoming dividend of US$2.25 per share at 3.0% yield

Full year 2023 earnings: EPS misses analyst expectations

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Inc. to Report Q4, 2023 Results on Feb 06, 2024

Amgen: Accelerating The Business And Dividend Growth

Is Amgen Inc. (NASDAQ:AMGN) Trading At A 44% Discount?

Up 40%, 3%-Yielding Amgen Is Still One Of My Favorite Healthcare Stocks

Is Amgen (NASDAQ:AMGN) A Risky Investment?

Amgen Provides Regulatory Update on Status of LUMAKRAS (Sotorasib)

Amgen Inc. Announces Executive Changes

Here's Why Amgen (NASDAQ:AMGN) Has Caught The Eye Of Investors

Executive VP recently sold US$2.7m worth of stock

Executive VP notifies of intention to sell stock

Upcoming dividend of US$2.13 per share at 3.1% yield

Amgen Presents New Data from Phase 2 Trial of Dazodalibep in Sjogren's Syndrome at ACR 2023

Amgen Inc. Presents New Data That Show Blood Pressure Decides for Results Treated with Krystexxa (PegLOTICase)

Amgen Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS misses analyst expectations

Amgen Inc. to Report Q3, 2023 Results on Oct 31, 2023

Amgen Inc. Declares Dividend for the Fourth Quarter of 2023, Payable on December 8, 2023

Are Investors Undervaluing Amgen Inc. (NASDAQ:AMGN) By 46%?

Amgen Presents New LUMAKRAS (Sotorasib) Plus Vectibix (Panitumumab) Data in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer

Amgen Inc. to Present New Research from Oncolfolio and Pipeline At ESMO2023

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Is Amgen (NASDAQ:AMGN) Using Too Much Debt?

Amgen Presents New Lumakras® (Sotorasib) Plus Chemotherapy Data in First-Line Kras G12c Nsclc At Wclc

Do Amgen's (NASDAQ:AMGN) Earnings Warrant Your Attention?

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Amgen Presents Phase 2 OLPASIRan Data at ESC 2023

Amgen Announces to Discuss Application for LUMAKRAS (Sotorasib) for Treatment of KRAS G12C-Positive NSCLC at FDA Advisory Committee Meeting

Insider recently sold US$2.5m worth of stock

Insider notifies of intention to sell stock

Upcoming dividend of US$2.13 per share at 3.3% yield

Amgen Inc. Announces Management Changes

Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.13

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2023

Amgen Inc. to Report Q2, 2023 Results on Aug 03, 2023

Amgen Inc. Announces U.S. Food and Drug Administration Approves Supplemental Biologics License Application for BLINCYTO

Amgen Presents New Lumakras® (Sotorasib) Codebreak 200 CNS Data At Asco 2023

Amgen Presents New Scientific and Clinical Research Across its Diverse Oncology Portfolio and Pipeline at ASCO 2023

Amgen Presents New Research on Otezla® (Apremilast) in Psoriatic Arthritis At Eular 2023

Amgen Inc. (NASDAQ:AMGN) Shares Could Be 45% Below Their Intrinsic Value Estimate

Upcoming dividend of US$2.13 per share at 3.6% yield

Amgen (NASDAQ:AMGN) Is Paying Out A Larger Dividend Than Last Year

Amgen Inc. Announces New Data from A Real-World Study of Nearly Half of Million Postmenopausal Women with Osteoporosis in the U.S. Medicare Program

These 4 Measures Indicate That Amgen (NASDAQ:AMGN) Is Using Debt Reasonably Well

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.13

Amgen Inc. (NASDAQ:AMGN) Shares Could Be 37% Below Their Intrinsic Value Estimate

Consensus EPS estimates fall by 12%

Upcoming dividend of US$2.13 per share at 3.5% yield

AstraZeneca and Amgen Announce Approval of TEZSPIRE® (tezepelumab-ekko) in the US

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts